Cannabinoid treatment for autism: a proof-of-concept randomized trial

ConclusionsThis interventional study provides evidence that BOL-DP-O-01-W and BOL-DP-O-01, administrated for 3  months, are well tolerated. Evidence for efficacy of these interventions are mixed and insufficient. Further testing of cannabinoids in ASD is recommended.Trial registration ClinicalTrials.gov: NCT02956226. Registered 06 November 2016,https://clinicaltrials.gov/ct2/show/NCT02956226
Source: Molecular Autism - Category: Molecular Biology Source Type: research